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Key Clinical Message
A 60-year-old man with a pre-existing stable sacrococcygeal teratoma developed
acromegaly, ectopic Cushing’s syndrome, and 5HIAA secretion. To our knowl-
edge, this represents the first reported case of ACTH and serotonin secretion,
and likely GHRH or GH cosecretion, from a sacrococcygeal teratoma in an
adult.
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Case Description
A 60-year-old man presented with clinical features of acro-
megaly. He had a background of type 1 diabetes, diagnosed
aged 28 years, hypertension and a C3–C6 laminoplasty
aged 54 years for cervical stenosis. He had continued
surveillance following an exploration and partial resection
of a sacral dermoid cyst aged 8 years. CT imaging showed
a complex, partly cystic, partly solid presacral mass with
some erosion of the lower sacrum and coccyx (Fig. 1). The
cystic component had required intermittent radiological-
guided drainage to relieve abdominal pain.
Endocrine testing confirmed growth hormone (GH)
excess (nadir serum GH after 75 g oral glucose 9.8 mcg/L;
serum IGF-1 72.4 nmol/L (reference range 9.0–40.0)). The
pituitary gland was homogenous on T1-weighted magnetic
resonance imaging (MRI), with no focal mass lesion,
although with a convex superior margin. Repeat pituitary
imaging with T1- and T2-weighted and T1 dynamic
sequences showed no clear focal abnormality, but persistent
convexity of the superior aspect of the gland. Due to the
absence of a definite surgical target, he was initially treated
medically. However, dopamine agonist and somatostatin
analogue therapy were poorly tolerated due to unpredictable
hypoglycemic events and gastrointestinal side effects and,
after a period of time, medical therapy was stopped.
11C-methionine PET-CT coregistered with volumetric
MRI demonstrated diffuse hyperintensity within the pitu-
itary, but no discrete lesion. Somatostatin receptor
scintigraphy was reported to show physiological uptake
in the bladder and physiological uptake in the pituitary
sella. He underwent pituitary exploration and partial
transphenoidal hypophysectomy; histology revealed nor-
mal pituitary tissue only, but 3 months postoperatively
his serum IGF-1 was just 11 nmol/L (age-related refer-
ence range 5–26 nmol/L) and has remained normal
thereafter. Anterior pituitary function was otherwise nor-
mal postoperatively.
1768 ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
In the weeks preceeding surgery, he developed periph-
eral edema. Within weeks of surgery, he was admitted
with severe fluid retention and abdominal bloating. He
had gained 15 kg in weight with persistent hypokalemia
despite the use of potassium-sparing diuretics (amiloride,
spironolactone). There was no proteinuria, and serum
albumin was 30 g/L and he had normal cardiac function
as determined by MRI. A pulmonary embolus was identi-
fied on CT pulmonary angiogram but deemed not large
enough to cause cardiac strain, and there was no associ-
ated inferior vena cava obstruction to explain his edema.
He suffered recurrent infections: bilateral pneumonia, cel-
lulitis, influenza, and norovirus-associated gastroenteritis.
Cortisol excess was suspected and confirmed on a low-
dose dexamethasone suppression test (cortisol postdexam-
ethasone 1070 nmol/L) and an elevated midnight cortisol
(>1750 nmol/L). ACTH was elevated (188 ng/L; reference
range 0–40 ng/L); with all tests performed after resolution
of his acute illness. Postoperative cortisol ranged between
800 and 1728 nmol/L.
Ectopic ACTH production from the presacral mass was
considered, and a core biopsy of this lesion revealed a well-
differentiated neuroendocrine tumor with no mitoses seen
and a Ki-67 of 1% (WHO grade G1 [1]). Immunochemistry
demonstrated CAM5.2-positive cytokeratin immunoreac-
tivity and cytoplasmic staining for synaptophysin and
ACTH (Fig. 1). Immunostaining for other
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Figure 2. (A and B) T1-weighted axial magnetic resonance image (A)
and T1-weighted turbo inversion recovery magnitude (TIRM) coronal
magnetic resonance image. These demonstrate the large mixed fluid
containing (red arrows) and heterogeneous soft tissue (yellow) areas
of the presacral pelvic mass consistent with a teratodermoid
intimately connected to, and possibly involving the sacrum, with soft
tissue extension posterior to the posterior sacral contour.
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Figure 1. Histology of the trucut biopsy. (A) H&E showing a core of
well-differentiated neuroendocrine tumor with bland ovoid nuclei
arranged in a partially cribriforming and partly solid architecture. (B)
Immunochemistry showing strong positivity for ACTH in the vast
majority of cells. (C) Immunochemistry for CAM 5.2 showing a
perinuclear dot positivity, typical for neuroendocrine tumors.
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adenohypophysial hormones (including growth hormone)
was negative; however, there was only a small amount of tis-
sue. i(12)p was also negative, in keeping with teratomas aris-
ing in this region, and distinguishing this mature
sacrococcygeal teratoma from testicular-type mature ter-
atomas which in adult males have malignant potential [2].
Unfortunately, there was insufficient tissue for immunohisto-
chemistry for GHRH. Serum alpha-fetoprotein and beta-
HCG were normal and he had a normal testicular examina-
tion (Fig. 2).
Cushing’s syndrome was treated with a combination of
subcutaneous octreotide (to reduce ACTH secretion),
metyrapone, ketoconazole and, subsequently when eucor-
tisolemia could not be achieved, intravenous etomidate
2.5 mg/h. Once stabilized, he underwent bilateral
adrenalectomy with resultant normalization of serum
potassium and marked improvement of his edema.
Despite adrenalectomy and good recovery, he continued
to experience episodes of hypoglycemia, breathlessness,
and anxiety with labile blood pressure. 5-hydroxyindolea-
cetic acid (5HIAA) (153 lmol/24 h; reference range 4.7–
36.2 lmol/24 h) and chromogranin B (1416 pmol/L; refer-
ence range 0–150) were both elevated; chromogranin A
was normal. Although the raised 5HIAA was likely responsible
for some of these symptoms, they did not completely resolve
with low-dose somatostatin analogue treatment, despite
improvement of 5HIAA to 65.3 lmol/24 h, raising the possi-
bility of additional hormonal cosecretion. The most recent
ACTH was 47 ng/L (posthydrocortisone), and IGF-1 has
remained normal both prior to, and after, recommencing
somatostatin analogue.
Discussion
Sacrococcygeal teratomas usually show fully differentiated
tissue derived from the ectoderm, endoderm, and meso-
derm. A very small minority have malignant germ cell ele-
ments and may secrete alpha-fetoprotein or beta-HCG [3].
Most present in utero or in infancy with rectal or bladder
obstruction, or rarely weakness, pain, or paralysis [4]. A
recent study suggests that sacrococcygeal teratomas can be
divided into two distinct histological groups, with the pres-
ence of i(12)p associated with the presence of germ cell
tumor components [5]. Treatment is usually surgical with
complete resection or, if the teratoma is part of a mixed-
germ cell tumor, adjuvant platinum-based chemotherapy
may be considered.
In this case, core biopsy and immunohistochemistry con-
firmed the diagnosis of a neuroendocrine tumor within a
pre-existing and well-differentiated sacrococcygeal ter-
atoma that had been stable since childhood, now with
pluripotent neuroendocrine secretion. Surgery would be
challenging and would be highly likely to lead to an
ileostomy and bladder dysfunction and a significant risk of
neurological sequelae. Targeted radiotherapy (to the solid
component of the teratoma) has been considered, but has
been declined by the patient, and at present, the tumor size
remains stable.
Well-differentiated neuroendocrine tumors arising in
testicular teratomas are well recognized and usually
behave in an indolent fashion [6]. Growth hormone
secretion in a mature ovarian teratoma has been previ-
ously reported and this remains a possible source for the
GH secretion [7]. In addition, ovarian teratomas can
secrete thyroid hormones from mature thyroid tissue
(struma ovarii) leading to thyrotoxicosis in some cases
[8], as well as the rarer ovarian carcinoid neoplasms
secreting 5HIAA [9]. Ectopic GHRH secretion has been
observed in human pancreatic tumors [10], and in addi-
tion, GHRH has some structural similarity with other
peptides secreted within the gut such as VIP, glucagon,
and GIP, which are known to weakly stimulate the release
of growth hormone from the anterior pituitary [11].
However, certain aspects of our case remain to be fully
explained. For example, it is notable that there was no
sign of pituitary hyperplasia histologically in the sample
sent for analysis following transsphenoidal surgery (which
might be anticipated in the presence of ectopic GHRH
secretion); in addition, unfortunately there was insuffi-
cient tissue from the core biopsy of the sacrococcygeal
teratoma to permit staining for GHRH (and the patient’s
IGF-I was normal at the time of biopsy). It is possible
that due to tumor heterogeneity, GHRH or GH expres-
sion was present in unsampled areas of the tumor. Never-
theless, on balance, it seems most likely that our patient’s
neuroendocrine tumor was the origin of his acromegaly.
The cortisol hypersecretion (from ectopic ACTH) was
inadequately controlled by medication, necessitating bilat-
eral adrenalectomy. Previous case reports have suggested
the existence of ACTH-dependent Cushing’s syndrome in
a sacrococcygeal teratoma [12, 13]. Our patient is likely
to have had a sacrococcygeal teratoma, which was stable
for decades, but later in life resulted in acromegaly, then
switching to ACTH secretion (resulting in Cushing’s syn-
drome) and serotonin secretion. In addition, it is possible
that his current symptoms of breathlessness, hypo-
glycemia, and fluctuant blood pressure are secondary to
secretion of other unidentified peptide(s). To our knowl-
edge, this represents the first reported case of ACTH and
serotonin secretion, and possible GHRH or GH cosecre-
tion, from a sacrococcygeal teratoma in an adult.
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